Thioredoxin in sepsis: Just another biomarker or a plausible therapeutic target?

Critical Care Medicine

Volumn 37, Issue 7, 2009, Pages 2304-2305

  Burke Gaffney, Anne ^a   Evans, Timothy W ^a   Quinlan, Gregory J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Inflammation; Macrophage migratory inhibitory protein; Oxidative stress; Sepsis; Therapy; Thioredoxin

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; APOPTOSIS INHIBITOR; BIOLOGICAL MARKER; HYPERTENSIVE AGENT; MACROPHAGE MIGRATION INHIBITION FACTOR; OXIDOREDUCTASE; RECOMBINANT THIOREDOXIN; THIOREDOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; CELL GROWTH; CRITICALLY ILL PATIENT; DOWN REGULATION; EDITORIAL; FLUID RESUSCITATION; INFLAMMATION; INTENSIVE CARE UNIT; LUNG INJURY; MENINGOCOCCEMIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SEPSIS; ANIMAL; HUMAN; METABOLISM; NOTE; PHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; SEPSIS; THIOREDOXINS;

EID: 67649732909     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a606dc     Document Type: Editorial

References (14)

1. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
2. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
3. Bernard GR, Ely EW, Wright TJ, et al: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29:2051-2059
4. Hofer S, Rosenhagen C, Nakamura H, et al: Thioredoxin in human and experimental sepsis. Crit Care Med 2009; 37:2155-2159
5. Burke-Gaffney A, Callister ME, Nakamura H: Thioredoxin: Friend or foe in human disease? Trends Pharmacol Sci 2005; 26:398-404
6. Callister ME, Burke-Gaffney A, Quinlan GJ, et al: Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 2006; 61:521-527
7. Callister ME, Burke-Gaffney A, Quinlan GJ, et al: Persistently low plasma thioredoxin is associated with meningococcal septic shock in children. Intensive Care Med 2007; 33: 364-367
8. Nakamura H, Herzenberg LA, Bai J, et al: Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci USA 2001; 98:15143-15148
9. Calandra T, Echtenacher B, Roy DL, et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-170
10. Kondo N, Ishii Y, Son A, et al: Cysteine-dependent immune regulation by TRX and MIF/GIF family proteins. Immunol Lett 2004; 92:143-147
11. Sato A, Hara T, Nakamura H, et al: Thioredoxin-1 suppresses systemic inflammatory responses against cigarette smoking. Antioxid Redox Signal 2006; 8:1891-1896
12. Tamaki H, Nakamura H, Nishio A, et al: Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 2006; 131:1110-1121
13. Kudrin A, Ray D: Cunning factor: Macrophage migration inhibitory factor as a redoxregulated target. Immunol Cell Biol 2008; 86:232-238
14. Parrish WR, Gallowitsch-Puerta M, Czura CJ, et al: Experimental therapeutic strategies for severe sepsis: Mediators and mechanisms. Ann N Y Acad Sci 2008; 1144:210-236